RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival

V Goidts1, J Bageritz, L Puccio

  • 1Division of Molecular Genetics, German Cancer Research Center, Heidelberg, Germany. v.goidts@dkfz.de

Oncogene
|November 8, 2011
PubMed

Insights

Cancer stem-like cells (CSCs) drive glioblastoma recurrence. Targeting the PFKFB4 enzyme, crucial for CSC survival and linked to poor patient outcomes, offers a promising therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Cancer stem-like cells (CSCs) are implicated in glioblastoma (GBM) therapy resistance and recurrence.
  • Targeting CSCs presents a promising therapeutic strategy for primary brain tumors.

Purpose of the Study:

  • To identify novel genes and pathways crucial for brain CSC survival.
  • To discover potential therapeutic targets for glioblastoma treatment.

Main Methods:

  • RNA interference (RNAi) screening of the human kinome (682 targets) and phosphatome (180 targets).
  • In vitro validation of identified candidate genes in brain CSCs.
  • Correlation analysis of gene expression with patient survival data.

Main Results:

  • Identified 46 potential survival-related genes, including kinases and phosphatases.
  • Highlighted the prominent role of the metabolism gene PFKFB4 in brain CSC maintenance.
  • Found high PFKFB4 expression correlated with shorter survival in glioblastoma patients.

Conclusions:

  • The glycolytic pathway is essential for malignant glioma cells and brain CSCs.
  • PFKFB4 is a critical factor in brain CSC survival and a potential therapeutic target.
  • Tumor metabolism represents a promising therapeutic avenue for glioblastoma.